Materias dentro de su búsqueda.
Mostrando 486,401 - 486,420 Resultados de 487,202 Para Buscar '"free will"', tiempo de consulta: 2.26s Limitar resultados
  1. 486401
    “…Background: In a prior Phase III, randomized-withdrawal study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, provided rapid and sustained normalization of mean urinary free cortisol (mUFC) in most patients (pts) with CD. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Osilodrostat Is an Effective and Well-Tolerated Treatment for Cushing’s Disease (CD): Results From a Phase III Study With an Upfront, Randomized, Double-Blind, Placebo-Controlled Phase (LINC 4)
  2. 486402
    “…We examined IAIR, and the frequency of intra-amniotic inflammation (IAI) and EONS according to the progression of inflammation in CP [i.e., stage-0, inflammation-free CP; stage-1, inflammation restricted to subchorionic fibrin (SCF); stage-2, inflammation in connective tissue (CT) of CP but without chorionic vasculitis; and stage-3, chorionic vasculitis]. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Relationship Among Intra-Amniotic Inflammatory Response, The Progression of Inflammation in Chorionic Plate and Early-Onset Neonatal Sepsis
  3. 486403
    “…Such “matched therapy” improved by at least 1.3-fold the progression-free survival on matched therapy (PFS2) compared to PFS on prior therapy (PFS1) in 36% of cases, representing 6% of the enrolled patients. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
  4. 486404
    “…RESULTS: CHD1L was significantly upregulated in ovarian cancer tissues and patients with higher expression of CHD1L had a shorter relapse-free survival (P < 0.001) and overall survival (P < 0.001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    circ-PTK2 (hsa_circ_0008305) regulates the pathogenic processes of ovarian cancer via miR-639 and FOXC1 regulatory cascade
  5. 486405
    “…Using data from the Ontario Cancer Registry, we identified all women 15–39 years of age diagnosed with the most common cancers in AYAs (brain, breast, colorectal, leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, thyroid and melanoma) from 1992 to 2011 who lived at least 5 years recurrence-free (Exposed, n = 14,316). Women with a tubal ligation, bilateral oophorectomy or hysterectomy previous to their cancer diagnosis were excluded. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Risk of infertility in female adolescents and young adults with cancer: a population-based cohort study
  6. 486406
    “…MAIN OUTCOMES AND MEASURES: Distant recurrence–free interval (DRFI) by clinically used breast cancer markers was assessed using Kaplan-Meier and multivariable Cox proportional hazards analyses adjusted for age, period of primary diagnosis, tumor size (T1a and T1b [T1a/b], T1c, and T2), tumor grade (1-3), PR status (positive vs negative), Ki-67 status (low vs medium to high), and STO-3 clinical trial arm (tamoxifen treatment vs no adjuvant treatment). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial
  7. 486407
    “…In the two clinical cohorts treated with ICB, molecular groups with EGFR, HER2, ALK, ROS1, RET, or MET alterations had short progression-free survival (PFS; 1.8–3.7 months), while BRAF V600E group was associated with greater clinical benefit from ICB (CGDB cohort: PFS 9.8 months vs KRAS 3.7 months, HR 0.66, p=0.099; MDACC cohort: response rate 62% vs KRAS 24%; PFS 7.4 vs KRAS 2.8 months, HR 0.36, p=0.026). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
  8. 486408
    “…Together, PFMD has developed “how-to guides” for patient engagement that cover the main activities along the medicines development process. The guides are free to use and provide practical advice and examples that anyone can use in their patient engagement activities. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Co-creation of practical “how-to guides” for patient engagement in key phases of medicines development—from theory to implementation
  9. 486409
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Factors associated with soil-transmitted helminths infection in Benin: Findings from the DeWorm3 study
  10. 486410
    “…The detection of potential colorectal cancer (CRC) driver genes in ctDNA after nCRT indicated a significantly worse recurrence-free survival (RFS) (hazard ratio [HR] = 9.29, 95% CI = 3.74 to 23.10, P < 0.001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study
  11. 486411
    “…RESULTS: Iohexol pharmacokinetics was best described with a two-compartmental first-order elimination model, allometrically scaled to fat-free mass, with patient type as a covariate on clearance and the central distribution volume. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Model-Based Estimation of Iohexol Plasma Clearance for Pragmatic Renal Function Determination in the Renal Transplantation Setting
  12. 486412
    “…Patients treated with first-line crizotinib (n = 168) had significantly longer median progression-free survival (PFS) than chemotherapy (n = 67) (18.0 months vs. 7.0 months, p < 0.001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
  13. 486413
    por Shi, Yuankai, Lei, Kaijian, Jia, Yuming, Ni, Bingqiang, He, Zhiyong, Bi, Minghong, Wang, Xicheng, Shi, Jianhua, Zhou, Ming, Sun, Qian, Wang, Guolei, Chen, Dongji, Shu, Yongqian, Liu, Lianke, Guo, Zhongliang, Liu, Yong, Yang, Junquan, Wang, Ke, Xiao, Ke, Wu, Lin, Yi, Tienan, Sun, Debin, Kang, Mafei, Ma, Tianjiang, Mao, Yimin, Shi, Jinsheng, Tang, Tiegang, Wang, Yan, Xing, Puyuan, Lv, Dongqing, Liao, Wangjun, Luo, Zhiguo, Wang, Bin, Wu, Xiaohong, Zhu, Xiaoli, Han, Shuhua, Guo, Qisen, Liu, Rongyu, Lu, Zhiwei, Zhang, Jianyong, Fang, Jian, Hu, Changlu, Ji, Yinghua, Liu, Guolong, Lu, Hong, Wu, Dedong, Zhang, Junhong, Zhu, Shuyang, Liu, Zheng, Qiu, Wensheng, Ye, Feng, Yu, Yan, Zhao, Yanqiu, Zheng, Qinhong, Chen, Jun, Pan, Zhanyu, Zhang, Yiping, Lian, Wenjuan, Jiang, Bo, Qiu, Bo, Zhang, Guojun, Zhang, Hua, Chen, Yanju, Chen, Yuan, Duan, Hongbing, Li, Manxiang, Liu, Shengming, Ma, Lijun, Pan, Hongming, Yuan, Xia, Yuan, Xueli, Zheng, Yulong, Gao, Emei, Zhao, Li, Wang, Shumin, Wu, Can
    Publicado 2021
    “…Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression‐free survival (PFS), overall survival (OS), and safety. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first‐line treatment for Chinese patients with unresectable, metastatic, or recurrent non‐squamous non–small‐cell lung cancer: A multicenter, randomized, double‐blinded, phase III trial
  14. 486414
    “…BACKGROUND: COVID-19, the pandemic disease caused by infection with SARS-CoV-2, may take highly variable clinical courses, ranging from symptom-free and pauci-symptomatic to fatal disease. The goal of the current study was to assess the association of COVID-19 clinical courses controlled by patients’ adaptive immune responses without progression to severe disease with patients’ Human Leukocyte Antigen (HLA) genetics, AB0 blood group antigens, and the presence or absence of near-loss-of-function delta 32 deletion mutant of the C–C chemokine receptor type 5 (CCR5). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19
  15. 486415
    “…Plasma Aβ42/40 was measured using an immunoprecipitation-coupled mass spectrometry developed at Washington University (IP-MS-WashU), antibody-free liquid chromatography MS developed by Araclon (LC-MS-Arc), and immunoassays from Roche Diagnostics (IA-Elc); Euroimmun (IA-EI); and Amsterdam University Medical Center, ADx Neurosciences, and Quanterix (IA-N4PE). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease
  16. 486416
    “…The primary endpoint was the comparison of MRD levels (absolute MRD levels were categorised into two groups, low [<0·0001] and high [≥0·0001]) between patients with Down syndrome and acute lymphocytic leukaemia and matched controls, and the secondary outcomes were comparison of long-term outcomes (event-free survival, overall survival, relapse, and treatment-related mortality [TRM]) between patients with Down syndrome and acute lymphocytic leukaemia and matched controls. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study
  17. 486417
    por Harrewijn, Anita, Cardinale, Elise M., Groenewold, Nynke A., Bas-Hoogendam, Janna Marie, Aghajani, Moji, Hilbert, Kevin, Cardoner, Narcis, Porta-Casteràs, Daniel, Gosnell, Savannah, Salas, Ramiro, Jackowski, Andrea P., Pan, Pedro M., Salum, Giovanni A., Blair, Karina S., Blair, James R., Hammoud, Mira Z., Milad, Mohammed R., Burkhouse, Katie L., Phan, K. Luan, Schroeder, Heidi K., Strawn, Jeffrey R., Beesdo-Baum, Katja, Jahanshad, Neda, Thomopoulos, Sophia I., Buckner, Randy, Nielsen, Jared A., Smoller, Jordan W., Soares, Jair C., Mwangi, Benson, Wu, Mon-Ju, Zunta-Soares, Giovana B., Assaf, Michal, Diefenbach, Gretchen J., Brambilla, Paolo, Maggioni, Eleonora, Hofmann, David, Straube, Thomas, Andreescu, Carmen, Berta, Rachel, Tamburo, Erica, Price, Rebecca B., Manfro, Gisele G., Agosta, Federica, Canu, Elisa, Cividini, Camilla, Filippi, Massimo, Kostić, Milutin, Munjiza Jovanovic, Ana, Alberton, Bianca A. V., Benson, Brenda, Freitag, Gabrielle F., Filippi, Courtney A., Gold, Andrea L., Leibenluft, Ellen, Ringlein, Grace V., Werwath, Kathryn E., Zwiebel, Hannah, Zugman, André, Grabe, Hans J., Van der Auwera, Sandra, Wittfeld, Katharina, Völzke, Henry, Bülow, Robin, Balderston, Nicholas L., Ernst, Monique, Grillon, Christian, Mujica-Parodi, Lilianne R., van Nieuwenhuizen, Helena, Critchley, Hugo D., Makovac, Elena, Mancini, Matteo, Meeten, Frances, Ottaviani, Cristina, Ball, Tali M., Fonzo, Gregory A., Paulus, Martin P., Stein, Murray B., Gur, Raquel E., Gur, Ruben C., Kaczkurkin, Antonia N., Larsen, Bart, Satterthwaite, Theodore D., Harper, Jennifer, Myers, Michael, Perino, Michael T., Sylvester, Chad M., Yu, Qiongru, Lueken, Ulrike, Veltman, Dick J., Thompson, Paul M., Stein, Dan J., Van der Wee, Nic J. A., Winkler, Anderson M., Pine, Daniel S.
    Publicado 2021
    “…Structural magnetic resonance imaging data from children and adults (5–90 years) were processed using FreeSurfer. The main analysis included the regional and vertex-wise cortical thickness, cortical surface area, and subcortical volume as dependent variables, and GAD, age, age-squared, sex, and their interactions as independent variables. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cortical and subcortical brain structure in generalized anxiety disorder: findings from 28 research sites in the ENIGMA-Anxiety Working Group
  18. 486418
    “…By day 28, when compared with steroid use alone, IL-6RA use was associated with an adjusted incidence rate ratio (aIRR) of 1.12 (95% confidence interval [CI] 0.88, 1.4) for ventilator-free days, while combination therapy was associated with an aIRR of 0.83 (95% CI 0.6, 1.14). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: a preliminary report from a multinational registry
  19. 486419
    “…These included: 63/63 (100%) reactive/disease-free samples, 43/44 (98%) malignant and 4/4 (100%) benign non-hematopoietic tumors together with 28/38 (74%) leukemia/lymphoma cases; the only exception was Hodgkin lymphoma that required additional markers to be stained. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Flow Cytometry Immunophenotyping for Diagnostic Orientation and Classification of Pediatric Cancer Based on the EuroFlow Solid Tumor Orientation Tube (STOT)
  20. 486420
    “…The Cox model was used to investigate the associations of the clinical variables and DCE-MRI biomarkers with progression-free survival (PFS) and overall survival (OS). The objective response rate (ORR) was 10.8% (8/74) and the disease control rate (DCR) was 58.1% (43/74). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials
Herramientas de búsqueda: RSS